Free Trial
NASDAQ:ESLA

Estrella Immunopharma 5/14/2024 Earnings Report

Estrella Immunopharma logo
$1.02 +0.06 (+6.25%)
As of 10:03 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Estrella Immunopharma EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Estrella Immunopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Estrella Immunopharma Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Estrella Immunopharma's next earnings date is estimated for Friday, September 26, 2025, based on past reporting schedules.

Conference Call Resources

Estrella Immunopharma Earnings Headlines

Estrella Immunopharma (NASDAQ:ESLA) Trading Up 1% - Should You Buy?
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
See More Estrella Immunopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Estrella Immunopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Estrella Immunopharma and other key companies, straight to your email.

About Estrella Immunopharma

Estrella Immunopharma (NASDAQ:ESLA), a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

View Estrella Immunopharma Profile

More Earnings Resources from MarketBeat